Clinical course of sorafenib treatment in patients with hepatocellular carcinoma

Scandinavian Journal of Gastroenterology
Hyun Young WooMong Cho

Abstract

Sorafenib has been shown to improve survival of patients with advanced hepatocellular carcinoma (HCC). However, its tolerance in clinical practice has not been well evaluated, and whether sorafenib should be continued in cases of tumor progression or intolerance has not been established. The authors retrospectively assessed sorafenib tolerability, and evaluated the clinical course in patients who showed progression during sorafenib treatment. Between March 2008 and July 2010, 80 patients with advanced HCC were treated with sorafenib. With a median of 78.5 days of treatment, 15% discontinued sorafenib due to adverse events. The duration was significantly longer in patients with Child-Pugh class A liver function (233 ± 240 days) than in those with Child-Pugh class B (100 ± 136 days; p = 0.006). The overall progression rate was 53% (43/80), with a median time to progression of 105 days (95% confidence interval, 59-150 days). After progression, 14 patients received conservative care only (group 1), 14 continued sorafenib monotherapy (group 2), 6 changed to treatment without sorafenib (group 3) and 9 underwent additional treatment with concomitant sorafenib (group 4). Survival after progression was significantly better in groups 2, ...Continue Reading

References

Oct 13, 1999·Seminars in Liver Disease·J M LlovetJ Bruix
Mar 22, 2002·The Lancet Oncology·D M Parkin
Aug 7, 2003·Seminars in Radiation Oncology·Andy TrottiPhilip Rubin
Dec 12, 2003·Lancet·Josep M LlovetJordi Bruix
May 27, 2005·Seminars in Liver Disease·Lewis R Roberts, Gregory J Gores
Oct 27, 2005·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jordi BruixUNKNOWN Practice Guidelines Committee, American Association for the Study of Liver Diseases
Nov 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Melanie B Thomas, James L Abbruzzese
Mar 28, 2006·Cancer Letters·Roberta Pang, Ronnie T P Poon
Aug 16, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ghassan K Abou-AlfaLeonard B Saltz
Jul 25, 2008·The New England Journal of Medicine·Josep M LlovetUNKNOWN SHARP Investigators Study Group
Jan 16, 2009·The Oncologist·Matthias PinterMarkus Peck-Radosavljevic
Mar 20, 2010·European Journal of Gastroenterology & Hepatology·Violaine OzenneFrançoise Degos
Sep 3, 2011·Alimentary Pharmacology & Therapeutics·M PinterM Peck-Radosavljevic
Oct 1, 2011·Alimentary Pharmacology & Therapeutics·A HollebecqueP Mathurin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Related Papers

Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Giovan Giuseppe Di CostanzoMassimo De Luca
Anti-cancer Agents in Medicinal Chemistry
Hung HuynhIrene Wei Ling Lam
Hepatology : Official Journal of the American Association for the Study of Liver Diseases
Yu-Xiong FengDong Xie
© 2021 Meta ULC. All rights reserved